Arnav Kumar1, Kimi Sato1, Edlira Yzeiraj1, Jorge Betancor1, Lin Lin1, Balaji K Tamarappoo2, Deborah H Kwon1, Rory Hachamovitch1, Allan L Klein3. 1. Heart and Vascular Institute, Center for the Diagnosis and Treatment of Pericardial Diseases, Cleveland Clinic, Cleveland, Ohio. 2. Heart Institute, Cedars Sinai Medical Center, Los Angeles, California. 3. Heart and Vascular Institute, Center for the Diagnosis and Treatment of Pericardial Diseases, Cleveland Clinic, Cleveland, Ohio. Electronic address: kleina@ccf.org.
Abstract
OBJECTIVES: The aim of this study was to evaluate the prognostic value of quantitative assessment of pericardial delayed hyperenhancement (DHE) among patients with recurrent pericarditis (RP). BACKGROUND: Pericardial DHE on cardiac magnetic resonance may persist beyond the acute phase of pericarditis, suggesting continued pericardial inflammation. METHODS: This is a retrospective cohort study of 159 patients with RP who underwent DHE imaging and had a follow-up period of more than 6 months. Pericardial inflammation was quantified on short-axis DHE sequences by contouring the pericardium, selecting normal septal myocardium as a reference region, and then quantifying the pericardial signal that was >6 SD above the reference. Our primary outcome was clinical remission; secondary outcomes were time to recurrence and recurrence rate. RESULTS: The mean age of our patients was 46 ± 14 years, and 52% were women. During a median follow-up period of 23 months (interquartile range: 15 to 34 months), 32 (20%) patients achieved clinical remission. In the multivariable Cox proportional hazards model, lower quantitative pericardial DHE (hazard ratio: 0.77; 95% confidence interval: 0.64 to 0.93; p = 0.008) was independently associated with clinical remission. When added to background clinical and laboratory variables, quantitative pericardial DHE had incremental prognostic value over baseline clinical and laboratory variables (integrated discrimination improvement: 8%; net reclassification improvement: 36%). Furthermore, patients with a higher quantitative DHE had shorter time to subsequent recurrence (p = 0.012) and had a higher recurrence rate at 6 months (p = 0.026). CONCLUSIONS: Quantitative assessment of pericardial DHE was associated with clinical outcomes among patients with RP and provided incremental information regarding the clinical course of patients with RP.
OBJECTIVES: The aim of this study was to evaluate the prognostic value of quantitative assessment of pericardial delayed hyperenhancement (DHE) among patients with recurrent pericarditis (RP). BACKGROUND: Pericardial DHE on cardiac magnetic resonance may persist beyond the acute phase of pericarditis, suggesting continued pericardial inflammation. METHODS: This is a retrospective cohort study of 159 patients with RP who underwent DHE imaging and had a follow-up period of more than 6 months. Pericardial inflammation was quantified on short-axis DHE sequences by contouring the pericardium, selecting normal septal myocardium as a reference region, and then quantifying the pericardial signal that was >6 SD above the reference. Our primary outcome was clinical remission; secondary outcomes were time to recurrence and recurrence rate. RESULTS: The mean age of our patients was 46 ± 14 years, and 52% were women. During a median follow-up period of 23 months (interquartile range: 15 to 34 months), 32 (20%) patients achieved clinical remission. In the multivariable Cox proportional hazards model, lower quantitative pericardial DHE (hazard ratio: 0.77; 95% confidence interval: 0.64 to 0.93; p = 0.008) was independently associated with clinical remission. When added to background clinical and laboratory variables, quantitative pericardial DHE had incremental prognostic value over baseline clinical and laboratory variables (integrated discrimination improvement: 8%; net reclassification improvement: 36%). Furthermore, patients with a higher quantitative DHE had shorter time to subsequent recurrence (p = 0.012) and had a higher recurrence rate at 6 months (p = 0.026). CONCLUSIONS: Quantitative assessment of pericardial DHE was associated with clinical outcomes among patients with RP and provided incremental information regarding the clinical course of patients with RP.
Authors: Eias Massalha; Yafim Brodov; Daniel Oren; Alex Fardman; Sharon Shalom Natanzon; Israel Mazin; Roy Beinart; Ronen Goldkorn; Eli Konen; Elio Di Segni; Amit Segev; Roy Beigel; Shlomi Matetzky; Orly Goitein Journal: Front Cardiovasc Med Date: 2022-02-24
Authors: Jason N Johnson; Daniel B Loriaux; Elizabeth Jenista; Han W Kim; Anna Baritussio; Estefania De Garate Iparraguirre; Chiara Bucciarelli-Ducci; Vanessa Denny; Brian O'Connor; Saira Siddiqui; Kana Fujikura; Charles W Benton; Jonathan W Weinsaft; Jonathan Kochav; Jiwon Kim; Chaitanya Madamanchi; Michael Steigner; Raymond Kwong; Diego Chango-Azanza; Mónica Chapa; Sandra Rosales-Uvera; Puja Sitwala; Peter Filev; Anurag Sahu; Jason Craft; George J Punnakudiyil; Viraj Jayam; Farah Shams; Sean G Hughes; Jonan C Y Lee; Edward A Hulten; Kevin E Steel; Sylvia S M Chen Journal: J Cardiovasc Magn Reson Date: 2022-07-04 Impact factor: 6.903
Authors: Jan Berg; Marina Lovrinovic; Nora Baltensperger; Christine K Kissel; Jan Kottwitz; Robert Manka; Dimitri Patriki; Frank Scherff; Christian Schmied; Ulf Landmesser; Thomas F Lüscher; Bettina Heidecker Journal: Open Heart Date: 2019-04-23